If you are reading this message in plaintext or if you have an AOL address you must click on this link: http://listserv.otcjournal.com/otcjournal/20020119-1.html  and wait for a web page to automatically open up to properly read this newsletter. 
[IMAGE]		[IMAGE][IMAGE]	


[IMAGE]	


  [IMAGE] January 19, 2002 [IMAGE]   [IMAGE] Volume V, Issue 6 [IMAGE]     Email : info@otcjournal.com   URL : http://www.otcjournal.com    To OTC Journal Members:     [IMAGE] Special Note [IMAGE]  Many of you may have noticed Wednesday's edition of the OTC Journal did not arrive in your inbox until Thursday or Friday. There seems to be delivery challenges on the Internet which may be related to the recent demise of @Home. You can always visit http://listserv.otcjournal.com  to find our most current edition before it arrives in your mail. Please save this web address in your favorites on your browser.      [IMAGE] The BioTech Revolution- A Leading Group For the First Decade of the 21st Century   [IMAGE]  Vast fortunes were accumulated in the 80's and 90's as the computer evolved into an integral part of our daily lives. Companies like Microsoft, Cisco, Oracle, Intel, Sun Microsystems, and Dell Computer yielded massive profits for shareholders during the twenty five year meteoric growth phase of this industry.   The BioTech industry is poised to provide those same kind of returns in the first decade of the 21st Century. The fruits of innovative research will propel more new drugs to market than ever before. The paradigm has shifted from technology/internet companies to BioTech.   Serving as evidence of this paradigm shift is the recent "rebalancing" of the NASDAQ 100. Thirteen companies were booted off; all of them technology. Of the thirteen newly added; eight of them are BioTech.   During the 10 year period between 1976 and 1985 the FDA approved just 198 new drugs. Last year alone, the number of new drug approvals skyrocketed to 160. That figure is expected to climb even higher in 2002. At present, an astonishing 643 new pharmaceuticals are nearing the final stages of the FDA's testing and approval process according to a recent report prepared for the US Government. Enormous returns are likely for investors in the right companies as some of these 643 new therapies come to market.     [IMAGE] Factors Fueling the BioTech Revolution [IMAGE]  [IMAGE]  The chart of the biotech index reveals a 53% climb to the upside from the September low to the early December high. Stocks have given back ground recently as company guidance for the immediate future is sobering. This "reality" correction of the last three weeks has yielded a 50% retrenchment in the biotech index, suggesting entry levels are becoming attractive again.   The BioTech revolution is being fueled by many factors. Expedited FDA Approval procedures were implemented during the Clinton Administration, reducing the average clinical testing period from 15 years down to 5 years.   In addition, the recent breakthroughs in Human Genome Mapping have provided bio-scientists with revolutionary new tools to aid in identifying the underlying causes of disease and help accelerate the pace of the development of potential cures. Companies like Human Genome Sciences (NASDAQ: HGSI) are providing bio-scientists with exciting new tools to help speed the development of revolutionary treatments.   While it is estimated the FDA approval process requires an investment north of $150 million, the return on investment associated with a successful new drug introduction is staggering. 40% to 50% of new drugs making it to Stage III clinical trials never get approved, but successful approvals can generate billions in profits for drug companies.   In other parts of the world, barriers to entry are more relaxed for new drugs, causing increased competition, lower margins, and lower profits. Patent protection and stringent FDA requirements still keep the US pharmaceutical market positioned as the most coveted in the world.     [IMAGE] Potential Major Breakthroughs [IMAGE]  The following is a list of potential major breakthroughs for 2002:   ViroPharma (NASDAQ: VPHM): The Common Cold. ViroPharma is developing Picovir, purported to be the magic cure for the common cold. The company specializes in novel therapeutics for the treatment of diseases caused by RNA viruses. Such viruses are responsible for a host of common disorders, including certain types of meningitis, hepatitis, and the common cold. Many analysts feel an approval could be coming late this year for Picovir. Maxim Pharmaceuticals (NASDAQ: MAXM): Cancer Therapy. The Company's lead drug candidate, Ceplene?, is currently being tested in Phase 3 cancer clinical trials in 12 countries for malignant melanoma and acute myelogenous leukemia, and in Phase 2 trials for the treatment of hepatitis C and renal cell carcinoma. Medarex (NASDAQ: MEDX): Arthritis. Phase III trials were recently started on MDX-CD4, a treatment for rheumatoid arthritis. MDX-010 is currently undergoing several multi center Phase Phase I/II trials in prostate cancer, melanoma and other malignancies. Axcan Pharma (NASDAQ: AXCA): Ulcers and Other Stomach Problems. Axcan is a leading specialty pharmaceutical company within the field of gastroenterology in North America and Europe. This company posted fiscal year revenues of $104.5 million dollars and earnings of $11.5 million. Helicide, Axcan's patented, oral, single capsule, triple therapy treatment for H. Pylori infection (the leading cause of peptic ulcers and a potential cause of gastric cancer) should be FDA approved later this year. DUSA Pharmaceuticals (NASDAQ: DUSA): Cancer Detection. The company's main product Levulan
 PDT/PD is a platform used for the detection and treatment of a variety of superficial conditions, such as early cancers, pre cancers and skin conditions. Levulan apparently has wider applications and may add to the bottom line in the not too distant future. DUSA initiated three Phase I/II Levulan PDT clinical trials.  As mentioned earlier, 160 new drugs were approved by the FDA last year. There are currently 643 new drugs with a realistic chance of success in the FDA pipeline. Companies will make staggering profits as many of these new therapies come to market, and investors in the right stocks will enjoy the ride.     [IMAGE] Upcoming OTC Journal Profile [IMAGE]  The OTC Journal plans to focus a great deal of energy in the BioTech sector. This sector is high risk/high reward, and therefore fits with our theme. BioTech could replace computer technology as the boom group of the next decade, and we intend to participate with ideas for our members.   In the near future the OTC Journal will release a profile on an exciting medical device manufacturer that is benefiting from new drug therapies. The stock will open for trading on the American Stock Exchange. It is going public through an RTO, as described in our last edition . Therefore, all investors will be on equal ground once the stock begins trading. There will be no IPO stock allocated to preferred institutional investors at a substantial discount prior to the opening of trading.   The company is already generating significant revenues through one FDA approval, and another is imminent. Currently, there are nearly thirty new drugs in the FDA pipeline that could potentially benefit this company.   The company does not invest vast sums of capital in the FDA approval process. Their pharmaceutical partners do it for them, which mitigates a great deal of the risk associated with this type of investment.   Early stage investors include some of the most high profile names on Wall Street, seasoned industry experts, and pharmaceutical manufacturers.   Sound interesting? Stand by for Tuesday's edition for more details. The opportunity may come as soon as next Friday, January 25th, and you need to be ready to act if you want to be a ground floor participant.   Charts Provided Courtesy Of TradePortal.com    The OTC Journal is a proud partner of the SwingWire.com Online Investment Community . A next generation Online Analyst Exchange providing Members the ability to search, review, track and monitor some of the Internet's best Online CAs (CyberAnalysts). Members have the opportunity to potentially achieve higher returns by viewing top performing portfolios and receiving real-time alerts from favorite CAs.    SwingWire.com  also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts!    Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today!        Disclaimer   The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features.  Likewise, this newsletter is owned by MarketByte, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication.   Click Here  to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html  for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html  for Trading Alerts.   All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.   The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.   The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.   THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.   We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com . We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.     Unsubscribe Here     You can unsubscribe from this list at any time by Clicking Here  and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?email=andrew.h.lewis@enron.com .   	


[IMAGE]		
[IMAGE]		
[IMAGE]		
[IMAGE]		
[IMAGE]		
[IMAGE]		
[IMAGE]		
[IMAGE]		
[IMAGE]	[IMAGE]	

  
  ---
You are currently subscribed to otcjournal as: andrew.h.lewis@enron.com
To unsubscribe send a blank email to leave-otcjournal-3119263F@lyris.otcjournal.com